Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation

Molecular Cancer Therapeutics

Volumn 3, Issue 6, 2004, Pages 709-714

  Liu, Jie ^a   Li, Chengxiu ^a   Qu, Wei ^a   Leslie, Elaine ^a   Bonifant, Challice L ^b   Buzard, Gregory S ^c   Saavedra, Joseph E ^c   Keefer, Larry K ^b   Waalkes, Michael P ^a  

^a National Cancer Institute   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[O2 (2,4 DINITROPHENYL) 1 [(4 ETHOXYCARBONYL)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE]; [O2 (2,4 DINITROPHENYL) 1 [(4 N,N DIETHYLCARBOXAMIDO)PIPERAZIN 1 YL]DIAZEN 1 IUM 1,2 DIOLATE]; ANTINEOPLASTIC AGENT; ARSENIC; CISPLATIN; CN 3 100; GLUTATHIONE TRANSFERASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; NITRIC OXIDE DONOR; PRODRUG; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERANCE; ENZYME ACTIVATION; GENE OVEREXPRESSION; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ARSENIC; AZO COMPOUNDS; CELL LINE; CISPLATIN; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NITRIC OXIDE DONORS; PHOSPHORYLATION; PIPERAZINES; PLATINUM; PRODRUGS; RATS;

EID: 4444323426     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Tew KD, Ronai Z. GST function in drug and stress response. Drug Resist Updat 1999;2:143-7.
2. Gate L, Tew KD. Glutathione S-transferases as emerging therapeutic targets. Exp Opin Ther Targets 2001;5:477-89.
3. Townsend DM, Tew KD. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 2003;22:7369-75.
4. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3-23.
5. Borst P, Elferink PO. Mammalian ABC transporters in health and disease. Annu Rev Biochem 2002;71:537-92.
6. Shami PJ, Saavedra JE, Wang LY, et al. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity. Mol Cancer Ther 2003;2:409-17.
7. Ren Z, Kar S, Wang Z, Wang M, Saaredra JE, Carr BI. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways. J Cell Physiol 2003;197:426-34.
8. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci USA 1997;94: 10907-12.
9. Liu J, Chen H, Miller DS, et al. Overexpression of glutathione S-transferase π and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic. Mol Pharmacol 2001; 60:302-9.
10. - as nucleophile and leaving group in SNAr reactions. J Org Chem 2001; 66:3090-8.
11. Kushner S, Brancone LM, Flewitt RI, et al. Experimental chemotherapy of filariasis. V. The preparation of derivatives of piperazine. J Org Chem 1948;13:144-53.
12. Singhal SS, Piper JT, Srivastava SK, et al. Rabbit aorta glutathione S-transferases and their role in bioactivation of trinitroglycerin. Toxicol Appl Pharmacol 1996;140:378-86.
13. Keese MA, Bose M, Mulsch A, Schirmer RH, Becker K. Dinitrosyldithiol-iron complexes, nitric oxide (NO) carriers in vivo, as potent inhibitors of human glutathione reductase and glutathione-S-transferase. Biochem Pharmacol 1997;54:1307-13.
14. De Maria F, Pedersen JZ, Caccuri AM, et al. The specific interaction of dinitrosyl-diglutathionyl-iron complex, a natural NO carrier, with the glutathione transferase superfamily: suggestion for an evolutionary pressure in the direction of the storage of nitric oxide. J Biol Chem 2003;278: 42283-93.
15. Wong PS, Eiserich JP, Reddy S, Lopez CL, Cross CE, van der Vliet V. Inactivation of glutathione S-transferases by nitric oxide-derived oxidants: exploring a role for tyrosine nitration. Arch Biochem Biophys 2001; 394:216-28.
16. Lo BM, Nuccetelli M, Caccuri AM, et al. Human glutathione transferase P1-1 and nitric oxide carriers; a new role for an old enzyme. J Biol Chem 2001;276:42138-45.
17. Turella P, Pedersen JZ, Caccuri AM, et al. Glutathione transferase superfamily behaves like storage proteins for dinitrosyl-diglutathionyl-iron complex in heterogeneous systems. J Biol Chem 2003;278:42294-9.
18. Ji Y, Toader V, Bennett BM. Regulation of microsomal and cytosolic glutathione S-transferase activities by S-nitrosylation. Biochem Pharmacol 2002;63:1397-404.
19. Wang ZY. Arsenic compounds as anticancer agents. Cancer Chemother Pharmacol 2001;48 Suppl 1:S72-6.
20. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6 Suppl 2:3-10.
21. Brambila EM, Achanzar WE, Qu W, Webber MM, Waalkes MP. Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase. Toxicol Appl Pharmacol 2002;183: 99-107.
22. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17:931-40.
23. Shimizu M, Hochadel JF, Fulmer BA, Waalkes MP. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Toxicol Sci 1998;45:204-11.
24. Gregus Z, Gyurasics A. Role of glutathione in the biliary excretion of the arsenical drugs trimelarsan and melarsoprol. Biochem Pharmacol 2000;59:1375-85.
25. Kala SV, Neely MW, Kala G, et al. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 2000;275:33404-8.
26. Wang HF, Lee TC. Glutathione S-transferase π facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells. Biochem Biophys Res Commun 1993;192:1093-9.
27. Wang Z, Dey S, Rosen BP, Rossman TG. Efflux-mediated resistance to arsenicals in arsenic-resistant and -hypersensitive Chinese hamster cells. Toxicol Appl Pharmacol 1996;137:112-9.
28. Trimmer EE, Essigmann JM. Cisplatin. Essays Biochem 1999;34: 191-211.
29. Goto S, Yoshida K, Morikawa T, Urata Y, Suzuki K, Kondo T. Augmentation of transport for cisplatin-glutathione adduct in cisplatin-resistant cancer cells. Cancer Res 1995;55:4297-301.
30. Akiyama S, Chen ZS, Sumizawa T, Furukawa T. Resistance to cisplatin. Anticancer Drug Des 1999;14:143-51.
31. Gosland M, Lum B, Schimmelpfennig J, Baker J, Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 1996;16:16-39.
32. Konovalova NP, Goncharova SA, Volkova LM, Raevskaia TA, Eremenko LT, Korolev AM. Nitric oxide donor increases the effectiveness of cytostatic therapy and inhibits the development of drug resistance. Vopr Onkol 2003;49:71-5. (English Abstract PMID: 12715374)
33. Azizzadeh B, Yip HT, Blackwell KE, et al. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope 2001;111:1896-900.